vs
Axe Compute Inc.（AGPU）与AVANOS MEDICAL, INC.（AVNS）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是Axe Compute Inc.的20855.4倍（$180.9M vs $8.7K）。AVANOS MEDICAL, INC.净利率更高（-0.7% vs -1740028.0%，领先1740027.2%）。AVANOS MEDICAL, INC.同比增速更快（0.7% vs -1.3%）。过去两年Axe Compute Inc.的营收复合增速更高（33.6% vs 4.4%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
AGPU vs AVNS — 直观对比
营收规模更大
AVNS
是对方的20855.4倍
$8.7K
营收增速更快
AVNS
高出2.1%
-1.3%
净利率更高
AVNS
高出1740027.2%
-1740028.0%
两年增速更快
AGPU
近两年复合增速
4.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $8.7K | $180.9M |
| 净利润 | $-150.9M | $-1.3M |
| 毛利率 | — | 47.5% |
| 营业利润率 | -1990880.1% | 1.4% |
| 净利率 | -1740028.0% | -0.7% |
| 营收同比 | -1.3% | 0.7% |
| 净利润同比 | -6856.6% | 99.7% |
| 每股收益（稀释后） | — | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGPUAVNS
| Q4 25 | $8.7K | $180.9M | ||
| Q3 25 | $3.6K | $177.8M | ||
| Q2 25 | $2.7K | $175.0M | ||
| Q1 25 | $110.3K | $167.5M | ||
| Q4 24 | $8.8K | $179.6M | ||
| Q3 24 | $3.9K | $170.4M | ||
| Q2 24 | $67.3K | $171.7M | ||
| Q1 24 | $4.9K | $166.1M |
净利润AGPUAVNS
| Q4 25 | $-150.9M | $-1.3M | ||
| Q3 25 | $-77.7M | $-1.4M | ||
| Q2 25 | $-2.1M | $-76.8M | ||
| Q1 25 | $-2.4M | $6.6M | ||
| Q4 24 | $-2.2M | $-397.3M | ||
| Q3 24 | $-3.1M | $4.3M | ||
| Q2 24 | $-3.2M | $1.8M | ||
| Q1 24 | $-4.2M | $-900.0K |
毛利率AGPUAVNS
| Q4 25 | — | 47.5% | ||
| Q3 25 | -131.0% | 48.4% | ||
| Q2 25 | -579.4% | 52.6% | ||
| Q1 25 | 59.1% | 53.6% | ||
| Q4 24 | -250.5% | 54.6% | ||
| Q3 24 | -186.1% | 54.5% | ||
| Q2 24 | 79.4% | 55.7% | ||
| Q1 24 | -361.8% | 57.1% |
营业利润率AGPUAVNS
| Q4 25 | -1990880.1% | 1.4% | ||
| Q3 25 | -90654.1% | 0.1% | ||
| Q2 25 | -99174.8% | -42.6% | ||
| Q1 25 | -2073.3% | 6.1% | ||
| Q4 24 | -23848.9% | -233.0% | ||
| Q3 24 | -55296.7% | 7.0% | ||
| Q2 24 | -3664.6% | 3.7% | ||
| Q1 24 | -73734.7% | 2.4% |
净利率AGPUAVNS
| Q4 25 | -1740028.0% | -0.7% | ||
| Q3 25 | -2146264.3% | -0.8% | ||
| Q2 25 | -77198.4% | -43.9% | ||
| Q1 25 | -2214.6% | 3.9% | ||
| Q4 24 | -24676.9% | -221.2% | ||
| Q3 24 | -79208.9% | 2.5% | ||
| Q2 24 | -4730.1% | 1.0% | ||
| Q1 24 | -86843.2% | -0.5% |
每股收益（稀释后）AGPUAVNS
| Q4 25 | — | $-0.02 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-1.66 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $-8.64 | ||
| Q3 24 | — | $0.09 | ||
| Q2 24 | — | $0.04 | ||
| Q1 24 | — | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.8M | $89.8M |
| 总债务越低越好 | — | $90.3M |
| 股东权益账面价值 | $47.7M | $778.2M |
| 总资产 | $52.9M | $1.1B |
| 负债/权益比越低杠杆越低 | — | 0.12× |
8季度趋势，按日历期对齐
现金及短期投资AGPUAVNS
| Q4 25 | $10.8M | $89.8M | ||
| Q3 25 | $181.7K | $70.5M | ||
| Q2 25 | $506.1K | $90.3M | ||
| Q1 25 | $3.1M | $97.0M | ||
| Q4 24 | $611.8K | $107.7M | ||
| Q3 24 | $3.1M | $89.0M | ||
| Q2 24 | $5.3M | $92.2M | ||
| Q1 24 | $5.2M | $75.8M |
总债务AGPUAVNS
| Q4 25 | — | $90.3M | ||
| Q3 25 | — | $93.4M | ||
| Q2 25 | — | $95.7M | ||
| Q1 25 | — | $98.0M | ||
| Q4 24 | — | $125.3M | ||
| Q3 24 | — | $152.6M | ||
| Q2 24 | — | $164.9M | ||
| Q1 24 | — | $167.2M |
股东权益AGPUAVNS
| Q4 25 | $47.7M | $778.2M | ||
| Q3 25 | $-77.4M | $778.0M | ||
| Q2 25 | $-1.7M | $776.3M | ||
| Q1 25 | $-145.8K | $839.4M | ||
| Q4 24 | $-202.6K | $828.5M | ||
| Q3 24 | $2.0M | $1.2B | ||
| Q2 24 | $4.1M | $1.2B | ||
| Q1 24 | $4.1M | $1.2B |
总资产AGPUAVNS
| Q4 25 | $52.9M | $1.1B | ||
| Q3 25 | $3.1M | $1.1B | ||
| Q2 25 | $3.4M | $1.0B | ||
| Q1 25 | $5.9M | $1.1B | ||
| Q4 24 | $5.0M | $1.2B | ||
| Q3 24 | $7.5M | $1.7B | ||
| Q2 24 | $10.6M | $1.7B | ||
| Q1 24 | $10.6M | $1.7B |
负债/权益比AGPUAVNS
| Q4 25 | — | 0.12× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.13× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.9M | $28.2M |
| 自由现金流经营现金流 - 资本支出 | — | $21.3M |
| 自由现金流率自由现金流/营收 | — | 11.8% |
| 资本支出强度资本支出/营收 | 0.0% | 3.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $43.1M |
8季度趋势，按日历期对齐
经营现金流AGPUAVNS
| Q4 25 | $-3.9M | $28.2M | ||
| Q3 25 | $-1.7M | $14.0M | ||
| Q2 25 | $-3.3M | $6.8M | ||
| Q1 25 | $-985.8K | $25.7M | ||
| Q4 24 | $-2.1M | $57.9M | ||
| Q3 24 | $-2.5M | $23.0M | ||
| Q2 24 | $-3.2M | $27.8M | ||
| Q1 24 | $-3.4M | $-8.0M |
自由现金流AGPUAVNS
| Q4 25 | — | $21.3M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $-4.2M | ||
| Q1 25 | — | $19.0M | ||
| Q4 24 | $-2.1M | $53.1M | ||
| Q3 24 | — | $20.0M | ||
| Q2 24 | — | $21.9M | ||
| Q1 24 | $-3.4M | $-12.1M |
自由现金流率AGPUAVNS
| Q4 25 | — | 11.8% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | -2.4% | ||
| Q1 25 | — | 11.3% | ||
| Q4 24 | -23429.1% | 29.6% | ||
| Q3 24 | — | 11.7% | ||
| Q2 24 | — | 12.8% | ||
| Q1 24 | -70379.8% | -7.3% |
资本支出强度AGPUAVNS
| Q4 25 | 0.0% | 3.8% | ||
| Q3 25 | 0.0% | 3.9% | ||
| Q2 25 | 0.0% | 6.3% | ||
| Q1 25 | 0.0% | 4.0% | ||
| Q4 24 | 73.7% | 2.7% | ||
| Q3 24 | 0.0% | 1.8% | ||
| Q2 24 | 0.0% | 3.4% | ||
| Q1 24 | 62.4% | 2.5% |
现金转化率AGPUAVNS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.89× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 5.35× | ||
| Q2 24 | — | 15.44× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGPU
暂无分部数据
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
